Lu Ying, Jacobson Denise, Bousvaros Athos
Inflammatory Bowel Disease Center, Division of Gastroenterology, Children's Hospital Boston, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Inflamm Bowel Dis. 2009 Sep;15(9):1417-23. doi: 10.1002/ibd.20941.
Patients receiving immunosuppressive therapies may be at increased risk for complications of vaccine preventable diseases, including influenza, varicella, and pneumococcus. However, studies suggest that patients with chronic illness may be inadequately immunized. In part, this is because of a paucity of formal vaccine studies in immune compromised populations. This review discusses the methods one uses to assess vaccine efficacy and provides an update on currently known data on the vaccine antibody responses in immune compromised hosts. Currently published studies suggest that influenza vaccine can be safely administered to patients with IBD on immunosuppression, and is effective in the majority of patients. Further formal studies with other inactivated vaccines (e.g., pneumococcal vaccine, meningitis vaccine) should be conducted. While some studies in immune compromised hosts suggest the live attenuated varicella vaccine can be given without adverse events, administration of this vaccine in patients on immunosuppression remains controversial.
接受免疫抑制治疗的患者发生疫苗可预防疾病(包括流感、水痘和肺炎球菌)并发症的风险可能会增加。然而,研究表明慢性病患者的免疫接种可能不足。部分原因是免疫功能低下人群中缺乏正式的疫苗研究。本综述讨论了评估疫苗效力的方法,并提供了免疫功能低下宿主中疫苗抗体反应的当前已知数据的最新情况。目前发表的研究表明,流感疫苗可安全地用于接受免疫抑制治疗的炎症性肠病(IBD)患者,且对大多数患者有效。应开展关于其他灭活疫苗(如肺炎球菌疫苗、脑膜炎疫苗)的进一步正式研究。虽然免疫功能低下宿主的一些研究表明,减毒活水痘疫苗可以安全接种,但在接受免疫抑制治疗的患者中接种这种疫苗仍存在争议。